For example, several CCR1 antagonists have entered clinical trials, including CP-481,715 (Pfizer, New York, NY, USA) and MLN3897 (Millennium, New York, NY, USA) in rheumatoid arthritis trials, BX471 (Berlex/Scherring AG, Bothell, WA, USA) in multiple sclerosis, AZD-4818 (Astra-Zeneca, Cambridge, UK) in chronic obstructive disease spit, and BAY86-5047 for endometriosis [220,221]. The gene discussed is CCR1; the disease is multiple sclerosis.